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Anatomical and cellular localization of melatonin MT1 and MT2
receptors in the adult rat brain
Abstract: The involvement of melatonin in mammalian brain pathophysiology
has received growing interest, but information about the anatomical
distribution of its two G-protein-coupled receptors, MT1 and MT2, remains
elusive. In this study, using speciﬁc antibodies, we examined the precise
distribution of both melatonin receptors immunoreactivity across the adult rat
brain using light, confocal, and electron microscopy. Our results demonstrate
a selective MT1 and MT2 localization on neuronal cell bodies and dendrites in
numerous regions of the rat telencephalon, diencephalon, and mesencephalon.
Confocal and ultrastructural examination conﬁrmed the somatodendritic
nature of MT1 and MT2 receptors, both being localized on neuronal
membranes. Overall, striking diﬀerences were observed in the anatomical
distribution pattern of MT1 and MT2 proteins, and the labeling often
appeared complementary in regions displaying both receptors. Somadendrites
labeled for MT1 were observed for instance in the retrosplenial cortex, the
dentate gyrus of the hippocampus, the islands of Calleja, the medial habenula,
the suprachiasmatic nucleus, the superior colliculus, the substantia nigra pars
compacta, the dorsal raphe nucleus, and the pars tuberalis of the pituitary
gland. Somadendrites endowed with MT2 receptors were mostly observed in
the CA3 ﬁeld of the hippocampus, the reticular thalamic nucleus, the
supraoptic nucleus, the inferior colliculus, the substantia nigra pars reticulata,
and the ventrolateral periaqueductal gray. Together, these data provide the
ﬁrst detailed neurocytological mapping of melatonin receptors in the adult rat
brain, an essential prerequisite for a better understanding of melatonin distinct
receptor function and neurophysiology.
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Introduction
Melatonin (N-acetyl-5-methoxytryptamine) is a neurohor-
mone produced and released by the pineal gland and cir-
culating in the cerebrospinal ﬂuid (CSF) [1]. Melatonin is
implicated in several neurophysiological function including
circadian and seasonal rhythms, sleep, mood regulation
[2], and possesses anti-inﬂammatory and antioxidant prop-
erties at nonphysiological doses [3–5]. The physiological
actions of melatonin in brain are mediated by stimulation
of two high-aﬃnity G-protein-coupled receptors, respec-
tively, MT1 (also known as MTR1A or Mel-1a) and MT2
(also known as MTR1B or Mel-1b) [6, 7].
Despite a growing attention to the involvement of mela-
tonin in cerebral pathophysiology [8–10], information
about the anatomical distribution of MT1 and MT2 recep-
tors in the mammalian brain is scant. Binding sites for
2-[125I]iodomelatonin have been extensively mapped in the
CNS of rodents, monkeys, and humans [11–13]. In situ
hybridization and RT-PCR studies in rodents have identi-
ﬁed expression sites for melatonin receptors mRNAs in
the hippocampus [14] and the hypothalamus [15–17]. In
human postmortem tissue, MT1 receptors have been
observed for instance on cellular populations of the retina
[18] and MT2 receptor on pyramidal cells within subﬁelds
of the hippocampus [19].
Recently, we have reported part that MT2 receptors are
localized at somatodendritic level in rat brain regions
implicated in nonrapid eye movement (NREM) sleep [10].
The present study aims at characterizing the diﬀerential
anatomical distribution of both melatonin receptor pro-
teins across the adult rat brain using both light and elec-
tron microscopic immunohistochemistry, with selective
antibodies raised in one of our laboratories against both
the human MT1 and MT2 proteins [20]. We have thus pro-
vided the ﬁrst and long-awaited neuroanatomical mapping
of membrane melatonin receptors proteins in the rat brain,
at the cellular and subcellular levels, an essential prerequi-
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site for a better understanding of melatonin receptor func-
tions in mammals.
Material and methods
Animals
Adult male Sprague–Dawley rats (body weight: 225–250 g;
n = 15) were purchased from Charles River (St Constant,
QC, Canada). Housing was at constant temperature (21°C)
and humidity (60%), under a ﬁxed 12-hr light/dark cycle
and with free access to food and water. All experimental
procedures were conducted in accordance with the guide-
lines of the Canadian Council on Animal Care, and the
protocols were approved by the Animal Care Committee at
McGill University and Universite de Montreal.
Antibodies and reagents
Polyclonal anti-MT1 and anti-MT2 antibodies used in the
present immunohistochemical study were produced in our
laboratory as described previously [20]. Subsequently,
anti-MT2 antiserum was aﬃnity puriﬁed (Primm, Milan,
Italy). The sequences of the immunogenic peptides used to
generated MT1 and MT2 antisera are shown in Fig. 1(A).
Alignments between the human and rat MT1 and MT2
amino acid sequences are illustrated in Fig. 1(B) (BLASTP
suite at http://www.ncbi.nlm.nih.gov/). The antisera were
tested using a combination of immunological and func-
tional assays. Antisera were ﬁrst tested by immunocyto-
chemistry on NIH3T3 cells transfected with either MT1 or
MT2 cDNAs, with all due controls [20]. The transfected
cells were also functionally tested with iodomelatonin
radioligand binding assays [21, 22]. Subsequent work [19]
and ours showed that, in Western blotting (WB) assays,
antisera detected a band of the expected size (~40 kDa).
For both antisera, competition assays with speciﬁc pep-
tides prevented appearance of the bands, suggesting a high
speciﬁcity. In this study, controls included WB of rat cor-
tex, thalamus, and hypothalamus extracts (n = 3), omis-
sion of anti-MT1 or anti-MT2 primary antibodies (n = 2)
and preincubation of primary antibodies with a 100-fold
excess of their corresponding immunogenic peptide (n = 2)
(Fig. 1). In Western blots of rat brain regions, the anti-
bodies reacted with a band of ~40 kDa, corresponding to
the predicted molecular weight of the native receptor pro-
teins. For both receptors, incubation of WB membranes
with pre-immune sera (PIS) prevented appearance of the
bands (Fig. 1C), further demonstrating speciﬁcity. Note-
worthy, in a previously published immunohistochemical
study on rat brain tissue, we also reported a selective neu-
ronal labeling using the same anti-MT2 primary antibody
and associated speciﬁcity controls [10]. In preliminary
experiments on brain tissue from wild-type, MT1 KO and
MT2 KO mice, perfusion-ﬁxed and processed for immuno-
histochemistry, only ubiquitous, nonspeciﬁc staining of
neurons and glial cells was observed (results not shown),
precluding the use of these antibodies on mouse tissue.
The other antibodies were as follows: guinea pig antigli-
al ﬁbrillary acidic protein (GFAP; Synaptic Systems,
Goettingen, Germany), guinea pig antineuronal nuclei
(NeuN; Millipore Chemicon, Billerica, MA, USA), and
rat anticluster of diﬀerentiation molecule 11b (CD11b;
Serotec, Raleigh, NC, Canada). Secondary antibodies used
for light and electron microscopic immunohistochemistry
were either biotinylated goat anti-rabbit IgGs (Jackson
Immunoresearch, West Grove, PA, USA) or donkey anti-
rabbit IgGs conjugated to 0.8-nm colloidal gold particles
(Aurion, Wageningen, the Netherlands) to be revealed,
respectively, with the 3,30-diaminobenzidine (DAB)
substrate kit from Vector Labs (Burlingame, CA, USA) or
the HQ Silver enhancement kit from Nanoprobes
MT1  SCh
MT2  Rt
MT1 + peptide
MT2 + peptide
M
T
1
Cx Th
M
T
2
Cx Th
aT
aT
MT1humanNM_005958
MT1ratNM_053676.2
NNVVKVDSV
NNL I KVDSV
* * : : * * * * *
MT2humanNM_005959
MT2ratNM_001100641.1
GVQHQADAL
T I P VQEGAL
: * * *.
MT2 (Mel-1b) aminoacids 354–362: 
NH2-GVQHQADAL-COOH
MT1 (Mel-1a) aminoacids 341–350: 
NH2-NNVVKVDSV-COOH
PIS
Cx Hy
PIS
Cx Th
37 kDa
50 kDa
37 kDa
50 kDa
Hy
Hy
aT
aT
(A) (B)
(C) (D)
Fig. 1. Antibody speciﬁcity controls. (A)
Sequences of the immunogenic peptides
used to generate MT1 and MT2 antisera.
(B) Alignments between the human and
rat MT1 and MT2 amino acid sequences.
(C) Immunoblotting with anti-MT1
(1:5000), anti-MT2 (1:1000) and pre-
immune sera (PIS; 1:1000), and anti-
alpha tubulin (aT; 1:10,000) antibodies
on 30 lg of proteins loaded per lane. Cx:
suprahippocampal cortex, Th: thalamus,
Hy: hypothalamus. MT1 and MT2
receptors decorated bands of
approximately 40 kDa, at their expected
molecular weight. (D) As illustrated in
positive control brain regions, pre-
adsorption of primary antibodies with
their respective immunogenic peptide
completely prevented any
immunostaining SCh: suprachiasmatic
nucleus, Rt: reticular thalamic nucleus
(designated by arrows).
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(Yaphank, NY, USA). Species-speciﬁc IgGs conjugated to
Alexa Fluor488 or Alexa Fluor594 (Invitrogen Corpora-
tion, Grand Island, NY, USA) were used for double
immunoﬂuorescence and confocal microscopy.
Western blotting
Immunoblotting from homogenized suprahippocampal
cortex and thalamus was processed as described previously
[20]. In brief, extracts were protein assayed, loaded (30 lg)
in 4–12% Novex SDS-polyacrylamide gels (Life Technolo-
gies, Carlsbad, CA, USA), separated by electrophoresis,
and transferred to nitrocellulose membranes which were
then incubated (1 hr, RT) in a blocking buﬀer containing
5% nonfat milk in 0.1 M PBS and subsequently with rab-
bit anti-MT1 or anti-MT2 antibodies (overnight, 4°C),
diluted, respectively, 1:5000 and 1:1000 in 5% nonfat milk
in 0.1 M phosphate-buﬀered saline (PBS: 0.9% NaCl in
50 mM PB, pH 7.4) containing 0.15 mM NaCl and 0.1%
Tween-20 (Sigma, St. Louis, MO, USA)). Membranes were
further incubated (1 hr, RT) with horseradish peroxidase-
conjugated secondary (anti-rabbit) antibodies (1:150,000).
Loading controls were performed with mouse anti-alpha
tubulin diluted 1:10,000 (overnight, 4°C), followed by
anti-mouse horseradish peroxidase-conjugated secondary
antibodies (1:150,000), 1 hr, RT. Immunoreactive bands,
visualized by chemiluminescence (SuperSignal West Femto
Chemiluminescent Substrate; Thermo Fisher Scientiﬁc,
Rockford, IL, USA), were analyzed with a phosphorImag-
er (Scanner STORM 860; GE Health Care, Piscataway,
NJ, USA).
Immunohistochemistry
Animals (n = 12) were deeply anesthetized with sodium
pentobarbital (80 mg/kg, i.p.) and were perfused through
the heart with 250 ml of a ﬁxative solution, followed by
500 mL of 4% paraformaldehyde (PFA) in 0.1 mM phos-
phate buﬀer (PB). To avoid the possible inﬂuence of the
light/dark cycle on melatonin receptors immunolabeling
and subcellular localization, all animals were sacriﬁced in
standard condition at the same time of day (anesthesia, per-
fusion, and dissection always taking place between 10:00
and 11:00 am). For light (n = 9) and confocal (n = 3)
microscopy, the ﬁxative solution consisted in 0.5% acrolein
in 4% PFA prepared in 0.1 mM PB, pH 7.4. For electron
microscopy (n = 3), the ﬁxation protocol was modiﬁed to
improve the ultrastructural tissue preservation (2% acro-
lein in 1% PFA prepared in 0.2 mM PB), following earlier
immunoelectron studies of G-protein-coupled receptors in
brain [23, 24]. The brain and pituitary gland were carefully
removed, postﬁxed in 4% PFA (60 min, 4°C), and washed
in PBS. Fifty micrometer-thick coronal brain sections were
cut with a vibratome and processed free-ﬂoating. Pituitary
glands were further cryoprotected in 30% sucrose over-
night at 4°C and embedded in optimal cutting temperature
compound at 80°C. Twenty micrometer-thick tangential
sections were then obtained using a cryostat and processed
on gelatin-coated microscope slides.
For single immunoperoxidase labeling and light micros-
copy, sections were immersed (20 min) in 3% hydrogen
peroxide (H2O2), rinsed in PBS, immersed (20 min) in
0.1% sodium borohydride in PBS, rinsed in PBS, and
preincubated (2 hr) in a blocking solution (BS) of PBS con-
taining 10% normal goat serum (Vector Labs), 0.5% gela-
tin, and 0.3% Triton X-100. Sections were then washed in
PBS, incubated overnight at RT with anti-MT1 (1:1000 in
BS) or anti-MT2 (1:250) antibody, rinsed in PBS, incubated
(2 hr) with biotinylated goat anti-rabbit IgGs (1:1000),
rinsed in PBS and incubated (1 hr) in a 1:1000 dilution of
horseradish peroxidase-conjugated streptavidin (Jackson
Immunoresearch). After washes in PBS, labeling was
revealed (2–5 min) with the DAB reagent kit. This reaction
was stopped in distilled water followed by washes in PB.
Sections were air-dried on slides, dehydrated in ethanol,
cleared in toluene, and coverslipped with DPX (Fluka,
Oakville, ON, Canada). Photomicrographs were taken at
low (1.69 objective), medium (6.39 objective), and high
(109 objective) magniﬁcations with a Leitz Diaplan optical
microscope coupled to an Olympus DP21 color digital cam-
era and software (Olympus Corporation, Tokyo, Japan).
These images were adjusted for brightness and contrast
using Adobe Photoshop (San Jose, CA, USA).
For single immunogold labeling and electron micros-
copy, Triton X-100 was omitted from the BS. Incubation
with anti-MT1 (1:500) or MT2 (1:200) primary antibodies
(36 hr, RT) was followed by rinses in PBS and incubation
overnight at RT in a 1:50 dilution of gold-labeled, anti-
rabbit donkey IgGs. After washes in PBS and sodium ace-
tate, the size of immunogold particles was silver-enhanced
(1.5 min), and the sections processed for electron micros-
copy as previously described [25]. In brief, sections were
osmicated, dehydrated, and ﬂat-embedded in Durcupan
resin (Sigma) between two sheets of Aclar plastic (EMS,
Hatﬁeld, PA, USA). Following polymerization (48 hr,
60°C), areas of interest were excised from the Aclar sheets
and glued at the tip of resin blocks. Ultrathin sections
were then cut from the block surface, collected on copper
grids, stained with Reynold’s lead citrate, and examined
under an CM100 electron microscope (Philips; Philips
Electronique, St. Laurent, QC, Canada) equipped with a
digital camera. Digital images were adjusted for brightness
and contrast with the Adobe Photoshop software.
For double immunoﬂuorescence and confocal micros-
copy, sections were preincubated 2 hr in BS, then overnight
(RT) with a mixture of anti-MT1 (1:1000) or anti-MT2
(1:250) antibodies and either anti-NeuN (1:1000), anti-
GFAP (1:500), or anti-CD11b (1:300) antibodies. After
washes in PBS, sections were further incubated for 3 hr with
a mix of species-speciﬁc Alexa Fluor 488- and 594-
conjugated IgGs (1:200 in BS). After rinses in 0.1 M PB and
distilled water, sections were mounted in Vectashield med-
ium for ﬂuorescence (Vector Labs) and observed with under
a Zeiss LSM510 confocal microscope (Carl Zeiss, Thorn-
wood, NY, USA), using sequential laser analysis. Images of
1024 9 1024 pixels were produced with the Zeiss LSM
image browser (v4.2.0) and framed in Adobe Photoshop.
Results
In WB of adult rat brain extracts (suprahippocampal cor-
tex, thalamus, and hypothalamus, Fig. 1C), MT1 and
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MT2 antibodies stained a band of ~40 kDa, corresponding
to the predicted molecular weight of the native receptor
proteins (Compute pI/Mw tool at http://web.expasy.org/
compute_pi/). Incubation of membranes with the pre-
immune serum (PIS) resulted in the absence of blotting
signal (Fig. 1C). On brain sections from positive control
regions (MT1: suprachiasmatic nucleus, SCh; MT2: reticu-
lar thalamic nucleus, Rt), pre-adsorption of the primary
antibodies with their respective immunogenic (blocking)
peptide completely prevented any immunostaining
(Fig. 1D), as did omission of the primary antibodies
(result not shown).
Overall, immuno-peroxidase and immuno-ﬂuorescent
stainings examined by light and confocal microscopy
(Figs 2–11) revealed a selective immunoreactivity of neu-
ronal cell bodies and dendrites in numerous brain regions
(see Table 1). Using double immunoﬂuorescence, as illus-
trated in Fig. 2 for the basal forebrain (MT1) and substan-
tia nigra (MT2), we conﬁrmed the neuronal phenotype of
MT1- and MT2-positive brains cells. Both MT1 and MT2
labelings colocalized with the neuronal marker NeuN
(Fig. 2A,D), but not with the typical astroglial (GFAP)
and microglial (CD11b) markers (Fig. 2B–F). Overall
(Figs 3–11), striking diﬀerences were observed in the over-
all localization pattern and density of MT1 and MT2
receptors. In regions immunoreactive for both receptors
(e.g. hippocampus), the labeling appeared often comple-
mentary. MT1 and MT2 immunostaining was absent from
several gray matter structures (e.g. lateral habenula) but
strong in others (e.g. substantia nigra). Melatonin receptor
immunoreactivity was absent from all white matter and
brain vasculature.
MT1 / NeuN
MT1 / GFAP
MT1 / CD11b
MT2 / NeuN
MT2 / GFAP
MT2 / CD11b
(A) (D)
(B) (E)
(C) (F)
Fig. 2. Phenotype of MT1- and
MT2-positive rat brain cells. (A–C) MT1
receptor immunoﬂuorescence (red) in the
basal forebrain. (D–F) MT2 receptor
immunoﬂuorescence (red) in the substantia
nigra. Double immunoﬂuorescence with
the neuronal marker NeuN (A, D; green),
the astroglial marker GFAP (B, E; green),
and the microglial marker CD11b (C, F;
green) conﬁrmed the exclusive neuronal
phenotype (arrows) of rat brain cells
endowed with melatonin receptors. Scale
bar: 50 lm.
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Cerebral cortex
Neurons endowed with MT1 or MT2 receptors were
observed in various subdivisions of the cerebral cortex,
with a generally sparse MT2 immunostaining and a higher
density for MT1 labeling (examples in Table 1). MT1-posi-
tive neurons were mostly found in layers II/III and V, and
MT2-positive neurons in deeper layers (V and VI) of
immunoreactive cortical regions. Medially, MT1 immuno-
reactivity was weak to moderate in the prefrontal (infra-
limbic, prelimbic, and cingulated) and frontal (secondary
motor) cortices, but appeared moderate to strong in the
dysgranular (RSD) and granular (RSG) retrosplenial cor-
tices (Fig. 3A–F and Table 1), in which MT2 immunoreac-
tivity was faint. MT2 immunolabeling was also barely
detectable in the medial prefrontal cortex. In RSG, MT1
immunoreactivity reached its maximal density above the
dorsal hippocampus (Fig. 3E,F), then decreased rostrally
and caudally. MT1 labeling in RSG was restricted to pyra-
midal layer II with dendrites ascending toward the pial
surface and organized in discrete bundles in layer I
(Fig. 3D,F). Laterally, weak to moderate MT1 and MT2
immunostaining was found in the frontal (primary motor
and area 3), parietal (somatosensory), and agranular insu-
lar cortices. Unlike MT2, which yielded a weak immuno-
staining in both entorhinal and piriform cortices, MT1 was
almost absent from these regions. Weak MT1 and MT2
immunoreactivity could be detected in the claustrum and
the endopiriform nucleus. Finally, almost exclusively,
weak MT1 labeling was observed in the occipital (visual)
and temporal (auditory) cortices (examples in Table 1).
Basal forebrain
Rostrally, within the olfactory tubercle, ventral to the
nucleus accumbens, strong MT1 labeling density was
clearly discernible in the islands of Calleja (ICj; Fig. 4A,
D), regions in which MT2 immunoreactivity was only
weak (see also Table 1). MT1 and MT2 labeling density
was comparably moderate in the ventral pallidum (VP),
B
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Fig. 3. Anatomical regions exclusively immunoreactive for the MT1 receptor. (A–F) rostral (A, B), middle (C, D), and caudal (E, F)
thirds of the anterior half of the retrosplenial cortex. As indicated by inserts, high magniﬁcations of A, C, and E are, respectively, shown
in B, D, and F. Stereotaxic coordinates are bregma 1.72 mm, interaural 7.28 mm (A, B); bregma 2.92 mm, interaural 6.08 mm (C,
D); bregma 4.20 mm, interaural 4.80 mm (E, F). (G–L) rostral (G, H), middle (I, J), and caudal (K, L) thirds of the habenular complex.
High magniﬁcations of G, I, and K are shown, respectively, in H, J, and L. Stereotaxic coordinates are bregma 2.64 mm, interaural
6.36 mm (G, H); bregma 3.36 mm, interaural 5.64 mm (I, J); bregma 3.96 mm, interaural 5.04 mm (K, L). Dashed inserts in H illus-
trate a higher magniﬁcation of the medial habenula where MT1-positive neurons appeared with a typical membrane labeling (arrows). See
main list for abbreviations. Scale bars: 250 lm in E, K; 125 lm in F, L.
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Fig. 4. Immunohistochemical localization of MT1 and MT2 receptors in the basal forebrain. (A–F) MT1 immunoreactivity in the rostral
(A, D), middle (B, E), and caudal (C, F) thirds of the basal forebrain. As indicated by inserts, high magniﬁcations of A, B, and C are
shown, respectively, in D, E, and F. (G–L) MT2 immunoreactivity in the rostral (G, J), middle (H, K), and caudal (I, L) thirds of the
basal forebrain. High magniﬁcations of G, H, and I are shown, respectively, in J, K, and L. Stereotaxic coordinates are bregma 2.16 mm,
interaural 11.16 mm (A, D, G, J); bregma 0.00 mm, interaural 9.00 mm (B, E, H, K); bregma 0.48 mm, interaural 8.52 mm (C, F, I,
L). See main list for abbreviations. Scale bars: 250 lm in I; 125 lm in L.
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Fig. 5. Immunohistochemical localization of MT1 and MT2 receptors in the septal area. (A–F) MT1 immunoreactivity in the rostral (A,
D), middle (B, E), and caudal (C, F) thirds of the septum. As indicated by inserts, high magniﬁcations of A, B, and C are, respectively,
shown in D, E, and F. Dashed inserts in E and F illustrate higher magniﬁcations of the medial septum where small MT1-positive neurons
were detected (arrows). (G–L) MT2 immunoreactivity in the rostral (G, J), middle (H, K), and caudal (I, L) thirds of the septum. High
magniﬁcations of G, H, and I are shown, respectively, in J, K, and L. Dashed inserts in K illustrate higher magniﬁcations of the medial
septum. Stereotaxic coordinates are bregma 1.44 mm, interaural 10.44 mm (A, D, G, J); bregma 0.48 mm, interaural 9.48 mm (B, E, H,
K); bregma 0.00 mm, interaural 9.00 mm (C, F, I, L). See main list for abbreviations. Scale bars: 250 lm in I; 125 lm in F and L.
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Fig. 6. Immunohistochemical localization of MT1 and MT2 receptors in the hippocampal formation. (A–F) MT1 immunoreactivity in the
rostral (A, D), middle (B, E), and caudal (C, F) thirds of the dorsal hippocampus. As indicated by inserts, high magniﬁcations of A, B,
and C are shown in D, E, and F, respectively. Few MT1-positive neurons were found in the CA1 ﬁeld (dashed inserts in D, arrows in E),
as in the hilus of the dentate gyrus (DG) (arrows in F). (G–L) MT2 immunoreactivity in the rostral (G, J), middle (H, K), and caudal (I,
L) thirds of the dorsal hippocampus. High magniﬁcations of G, H, and I are shown, respectively, in J, K, and L. MT2 labeling reminis-
cent of interneurons appeared strong in the CA3 ﬁeld (arrows in K) and generally moderate in the DG (arrows in L). Stereotaxic coordi-
nates are bregma 2.16 mm, interaural 6.84 mm (A, D, G, J); bregma 2.64 mm, interaural 6.36 mm (B, E, H, K); bregma 3.24 mm,
interaural 5.76 mm (C, F, I, L). See main list for abbreviations. Scale bars: 250 lm in I; 125 lm in F and L.
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while only MT1 receptors could be detected in the shell of
the nucleus accumbens (AcbSh), particularly in its lateral
aspect (LAcbSh). From bregma and caudally, moderate
MT1 and MT2 immunoreactivity was also found in the VP
and in the medial forebrain bundle (mfb; e.g., Fig. 4E,K),
while weak to moderate MT1 immunostaining could be
observed in the basal portion of the substantia innominata
(SIB; Fig. 4F). Melatonin receptors were absent from sev-
eral structures of the basal forebrain, like the intermediate
endopiriform nucleus (IEn) and both the medial and lat-
eral preoptic areas (respectively, LPO and MPA).
Amygdala
Both melatonin receptors were almost absent from the
amygdala complex. Rostrally, where no MT2 receptor
could be detected, MT1 immunoreactivity was weak in the
medial division of the central amygdaloid nucleus (CeM),
and moderate in the anteroventral portion of the medial
amygdaloid nucleus (MeAV). Caudally, where no MT1
receptors could be seen, a weak MT2 labeling density was
observed in the amygdalo-piriform transition (APir) and
in the posteromedial part of the amygdalo-hippocampal
area (AHiPM).
Septal area
Both melatonin receptors were found in distinct structures
along the rostrocaudal extent of the septum, but MT1
immunoreactivity was mainly observed in its rostral
aspect, laterally, and MT2 immunoreactivity along the
whole anteroposterior axis, medially (Fig. 5). Rostrally,
MT1 labeling density was strong in the major island of
Calleja (ICjM) and only weak in the medial septal nucleus
(MS), as in the vertical limb of the diagonal band of Broca
(VDB; Fig. 5A,D). In the same areas, moderate MT2 im-
munostaining was restricted to the MS and VDB
(Fig. 5G,J). Caudally, while MT2 labeling density stained
moderately in the MS and became strong in the lambdoid
septal zone (Ld; Fig. 5H,K), MT1 immunoreactivity
decreased to a weak density in the MS (Fig. 5E,F). All
other subdivisions of the septum were immunonegative for
both melatonin receptors, including the three portions of
the lateral septal nucleus (intermediate, LSI; ventral, LSV;
and dorsal, LSD).
Hippocampus
As illustrated for the dorsal hippocampus (Fig. 6), a dif-
fuse MT1 labeling and a more distinct MT2 labeling were
observed in this brain region (Fig. 6 and Table 1). In the
CA1 ﬁeld, few MT1-positive neurons were found in the
pyramidal cell layer (Py), mostly rostrally, while a diﬀuse
MT1 labeling was observed in the stratum oriens (Or) and
radiatum (Rad) (Fig. 6D,E). MT1 staining density was
only weak in the CA2 and weak to moderate in the CA3.
MT2 immunoreactivity suggestive of interneurons,
scattered throughout layers [26], appeared of moderate
density in the CA1, weak in the CA2, whereas strong
labeling density was observed in the CA3 region where
MT2-immunoreactive cell bodies were more concentrated
in the Py layer (Fig. 6H,I,K). In the dentate gyrus (DG),
only weak and diﬀuse MT1 immunoreactivity was
observed. MT1-positive cell bodies were found in the hilus
of the DG, scattered in the polymorph layer (PoDG), and
precisely aligned along the subgranular zone, while the
granular layer (GrDG) remained MT1-immunonegative
(Fig. 6F). As in other parts of the hippocampal formation,
MT2 immunoreactivity was generally moderate in the DG
(Fig. 6I,L). Somatodendritic MT2 labeling could be
observed in the hilus, in the inner third of the CA3, as well
as in the dorsal portion of the GrDG, while both MoDG
and ventral GrDG were MT2-negative (Fig. 6L). Weak
MT2 immunoreactivity could be found in the PoDG.
Basal ganglia
In telencephalic basal ganglia, namely the striatum
(nucleus accumbens, caudate-putamen) and the globus
pallidus (GP), low MT1 and MT2 receptor immunoreac-
tivity was consistently detected (Table 1). Both receptors
were absent from the nucleus accumbens (Acb), except
for a weak MT1 density in the lateral portion of the Acb
shell (LAcbSh) where few immunopositive neurons
appeared scattered between the anterior commissure and
the ICj. In addition, no melatonin receptor whatsoever
was found along the whole rostrocaudal extent of the
caudate-putamen (striatum). In the GP, however, weak to
moderate MT2 immunostaining was observed. Medial
and inferior to the GP, a moderate MT1 and MT2
immunoreactivity was detected in the nucleus basalis of
Meynert (NBM).
Epithalamus
While MT2 immunoreactivity was absent from the whole
habenular complex, a strong MT1 labeling density
appeared restricted to the medial habenula (MHb;
Fig. 3G–L; see also Table 1). In the anterior portion of
the habenula, MT1-positive neurons were found to be
numerous in the ventromedial aspect of the MHb (Fig. 3H
and insert). In the middle portion of the habenula and
caudally, moderate and strong MT1 labeling density was
found in the ventromedial and ventrolateral MHb, respec-
tively (Fig. 3I–L). Only weak MT1-immunoreactivity
could be observed in the lateral habenula (LHb), mainly
in its medial half (LHbM).
Thalamus
In general, MT1 and MT2 immunostaining appeared com-
plementary in the thalamus (Fig. 7 and Table 1). MT1
immunoreactivity was almost exclusively associated with
dendritic proﬁles, whereas numerous MT2 cell bodies
could be observed in various areas. In the anterior third of
the thalamus, a moderate MT1 labeling density appeared
restricted to the anterodorsal nucleus (AD), immediately
lateral to the stria medullaris (sm; Fig. 7A,D). Only weak,
diﬀuse MT1 immunoreactivity was found in the ventrolat-
eral (VL), ventral anterior (VA), and rhomboid (Rh)
nuclei. At the same level, density of MT2-positive cell
bodies and their proximal dendrites was weak in the
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mediodorsal (MD), central medial (CM), anteromedial
(AM), and VL nuclei and moderate in the Rt (Fig. 7G,J).
In the middle and posterior thirds of the thalamus, in
addition to a moderate MT1 labeling density in the dorso-
medial part of the laterodorsal nucleus (LDDM; Fig. 7B,
E), numerous cross-sectioned MT1-positive dendritic pro-
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(E, F) thirds of the hypothalamus. As indicated by inserts, high magniﬁcations of A, C, and E are shown in B, D, and F, respectively.
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bregma 6.24 mm, interaural 2.76 mm (K, L). See main list for abbreviations. Scale bars: 250 lm in E, K; 125 lm in F, L.
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ﬁles could be observed in the dorsal lateral geniculate, ven-
tral posterolateral (VPL), ventral posteromedial (VPM),
and ventromedial (VM) nuclei (Fig. 7F). Few MT1-posi-
tive cell bodies were found in the CM and Rh nuclei, and
more abundantly in the caudal half of the submedius
nucleus. In the same area, MT2 labeling density was weak
in the centrolateral (CL), MD, VPM, and posterior tha-
lamic (Po) nuclei, moderate in the caudal part of the VL
nucleus, but strong in the Rt and VM nuclei (Fig. 7K,L).
Both melatonin receptors were absent from various dorsal
thalamic nuclei, like the paraventricular (PV), ventrolat-
eral laterodorsal (LDVL), and lateroposterior (LPLR and
LPMR) nuclei.
Hypothalamus
Rostrally, few MT1-positive somadendrites were observed
in the peduncular part of the lateral hypothalamus (PLH).
While the suprachiasmatic nucleus (SCh) displayed a mod-
erate to strong MT1 density (Fig. 1D), only few MT1-posi-
tive neurons were detected caudally in its ventromedial
division (SChVM). In the same anterior hypothalamic seg-
ment, MT2 labeling density was weak in the ventral PLH,
moderate in the magnocellular preoptic (MCPO), and
strong in the supraoptic (SO) nuclei (Fig. 8A,B). Caudally,
MT1 labeling density was very weak in the dorsal dorso-
medial (DMD), perifornical (Pe), and submammillotha-
lamic (SMT) nuclei. MT2 labeling was weak in the
perifornical area and moderate in the paraventricular
nucleus (PaV) and medial eminence (ME) (Fig. 8C–F).
Melatonin receptor immunoreactivity was absent from
other hypothalamic areas.
Pituitary
The pituitary gland, lodged in the hypophyseal fossa and
connected to the base of the hypothalamus by the infun-
dibulum (Inf), displayed a very speciﬁc pattern of melato-
nin receptor staining (Fig. 9). While the pars nervosa
(PN), pars intermedia (PI), and pars distalis (PD) were
MT1- and MT2-immunonegative (Fig. 9A–D), both the
pars tuberalis (PT) and the transitional area (TA) between
the PN and the Inf displayed a moderate to strong MT1
labeling density (Fig. 9A,B).
Dorsal mesencephalon
MT1- and MT2-positive cellular elements were detected in
both the superior (SC) and inferior (IC) colliculi
(Table 1). Rostrally, in the dorsal aspect of the SC, a
region deprived of MT2 immunoreactivity, a dense net-
work of MT1-positive dendrites was observed in the
zonal (Zo) and superior gray (SuG) layers, even denser
along the medial line. MT1 labeling density appeared
moderate in the optic nerve layer (Op) and almost absent
from the ventral SC layers (InG, intermediate gray;
InWh, intermediate white; DpG, deep gray; DpWh, deep
white). MT2 labeling density of cellular bodies and their
proximal dendrites was weak in the Op and moderate in
the InG. Caudally, MT1- and MT2-immunoreactive so-
madendrites were detected in various subdivisions of the
IC. While only a weak MT2 labeling density could be
observed in superﬁcial (cortical) layer 1 of the IC, mela-
tonin receptor density appeared weak to moderate in cor-
tical layers 2 and 3, as in the external and dorsal IC
cortices (respectively, ECIC and DCIC).
Periaqueductal gray
In the rostral third of the periaqueductal gray (PAG),
MT1 labeling density was weak in the dorsomedial
(DMPAG), dorsolateral (DLPAG), lateral (LPAG), and
ventrolateral (VLPAG) subdivisions, but moderate in the
dorsal raphe nucleus (DR) where MT1-positive neurons
were densely packed in the ventral aspect of the nucleus
Table 1. Distribution of MLT receptors immunoreactivity in the
adult rat brain
Selected brain regions MT1 density MT2 density
Telencephalon
Cerebral cortex
Prefrontal + – (+)
Retrosplenial +++ +
Occipital + –
Basal forebrain
Islands of Calleja +++ +
Medial forebrain bundle ++ ++
Ventral pallidum ++ ++
Hippocampus
CA1 + +
CA2 + + (+)
CA3 + (+) +++
Dentate gyrus + ++
Basal ganglia
Nucleus accumbens – (+) –
Caudate-putamen – –
Globus pallidus + + (+)
Diencephalon
Epithalamus
Lateral habenula + –
Medial habenula +++ –
Thalamus
Anterodorsal nucleus ++ –
Reticular nucleus – +++
Ventromedial nucleus + ++
Hypothalamus
Paraventricular nucleus – +
Supraoptic nucleus – +++
Medial eminence + ++
Suprachiasmatic nucleus ++ (+) –
Mesencephalon
Dorsal mesencephalon
Superior colliculi +++ +
Inferior colliculi ++ (+) ++ (+)
PAG
Ventrolateral PAG + ++
Dorsal raphe nucleus ++ +
Ventral mesencephalon
Substantia Nigra pars compacta ++ (+) +
Substantia Nigra pars reticulata + ++ (+)
Pituitary gland
Pars tuberalis +++ –
PAG, periaqueductal gray. Semiquantitative estimates of immu-
nocytochemical density are denoted as: –, no immunostaining; +,
weak; ++, moderate; +++, strong; intermediate levels are indicated
in brackets.
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(DRV) and in between the medial longitudinal fasciculi
(mlf; Fig. 10A,D; see also Table 1). In the same region,
MT2 immunoreactivity was absent from the DMPAG,
DLPAG, and LPAG, but a weak MT2 labeling density
was could be observed in the VLPAG (Fig. 10J), as in the
DR, where only few cell bodies appeared scattered across
the nucleus. The overall distribution of melatonin receptor
immunoreactivity in the middle third of the PAG was sim-
ilar, except that MT1 labeling density was weaker in the
DRV (Fig. 10E) and MT2 immunostaining slightly denser
in the VLPAG (Fig. 10K,L). In the caudal third, where
the dorsal and lateral PAG subdivisions consist of a thin
layer, MT1 immunoreactivity became moderate in the
VLPAG (Fig. 10F) and almost absent from the DR, while
MT2 labeling density was moderate to strong in the
VLPAG (Fig. 10L).
Ventral mesencephalon
In the rostral half of the mesencephalon, posterior to the
subthalamic area and ventral to the mesencephalic reticu-
lar formation (mRT), melatonin receptor immunoreactiv-
ity was particularly obvious in the substantia nigra (SN;
Fig. 11 and Table 1). A dense MT1 immunostaining was
observed in the dorsal, medial, and ventral tiers of the SN
pars compacta (respectively, SNCD, SNCM, and SNCV;
Fig. 11A–F). In SNC, MT1 immunoreactivity was almost
exclusively dendritic, with few MT1-positive cell bodies
detected. In the SN pars reticulata (SNR), several MT1-
positive neurons were seen, particularly in the lateral and
ventral SNR (Fig. 11D,E). MT2 labeling density was
almost null in the SNC and appeared moderate to strong
in the SNR, with clearly distinguishable immunopositive
somadendrites (Fig. 11G–L). Despite being present along
the whole rostro-caudal extent of the SNR, MT2-positive
neurons were more frequently observed in the lateral
SNR, rostrally (Fig. 11G,J), and in the ventral SNR, cau-
dally (Fig. 11I,L). Dorsomedial to the SN, MT2 immuno-
staining was particularly dense in the oculomotor (3N)
and pararubral (PaR) nuclei, as well as in the magnocellu-
lar (RMC) and parvocellular (RPC) parts of the red
nucleus (Fig. 8G–L). Medially, a weak MT1 immunoreac-
tivity could be observed in the rostral and lateral interpe-
duncular subnuclei (IPR and IPC), two regions that
appeared MT2-negative (Fig. 8I,K). In the ventral tegmen-
tal area (VTA), both melatonin receptors were found at a
very low staining density. Finally, in the caudal half of the
mesencephalon, posterior to the SC and ventral to the mlf,
several structures were MT1- and/or MT2-immunopositive.
Principally, from rostral to caudal, MT1 labeling density
appeared weak in the oral part of the pontine reticular
nucleus (PnO) and moderate in the median raphe (MnR),
medial paralemniscal (MPL), and ventral tegmental (VTg)
nuclei. MT2 labeling density appeared weak in the subpe-
duncular tegmental (SPTg), reticulotegmental (RtTg), and
MnR nuclei, moderate in the PnO, and strong in the VTg.
Cellular localization of melatonin receptors
Immunogold labeling examined by electron microscopy
conﬁrmed the exclusive somatodendritic localization of
melatonin receptors, with the detection of immunoreactive
cell bodies and dendrites only (Fig. 12). Ultrastructurally,
as expected for G-protein-coupled receptors, both MT1
(Fig. 12A–F) and MT2 (Fig. 12G–L) appeared mainly
localized at the plasma membrane, with only a small pro-
portion of cytoplasmic localization that increased toward
the cell body. In all regions examined, the cytoplasmic
proportion of immunogold particles was generally low,
but slightly higher for the MT2 receptor.
Discussion
This study is the ﬁrst attempt to describe, using immuno-
histochemistry, the neuroanatomical and subcellular local-
ization of both melatonin MT1 and MT2 receptor proteins
across the rat brain. Previous studies have reported the
existence of high-aﬃnity binding sites for melatonin or
localized mRNA expression of melatonin receptors [27].
But until now, the lack of selective antibodies for the
detection of MT1 and MT2 proteins has restricted the
knowledge about the sites of action of melatonin in the
CNS. Here, we detected the presence of each receptor in
numerous brain regions, and we found that both MT1 and
MT2 receptors are expressed by neurons, but not by glial
cells. We conﬁrmed the presence of MT1 and/or MT2
receptors in areas previously known for their high concen-
tration in melatonin binding sites, such as the SCh [28–31]
and the pars tuberalis of the pituitary gland [32–36], and
we found a distinct presence of MT1 and MT2 receptor
proteins in diﬀerent brain areas suggesting a distinctive
localization and thus function of each receptor in neuro-
physiological and neuropathological contexts [2].
With immunohistochemistry, melatonin receptor immu-
nolabeling was found in numerous brain regions. Origi-
nally, melatonin binding sites in the rat pituitary gland
and brain were described predominantly in the median
eminence, the SCh, the area postrema, the paraventricular
thalamic nucleus, as well as the hypothalamus, the hippo-
campus, the parietal cortex, and the striatum [37–39].
More binding sites were later added to the list, including
the pars tuberalis of the pituitary gland, the medial region
of the lateral habenula, the arcuate nucleus, and the amyg-
dala [40]. MT1 receptor mRNA has been detected in the
rodent dorsal striatum, nucleus accumbens, olfactory
tubercle, substantia nigra, and ventral tegmental area
(VTA) [41]. MT1 and MT2 receptor mRNA expressions
have been reported in the SCN and vestibular nuclei [42,
43]. In humans, MT1 mRNA and protein have been
detected in areas including the hypothalamus, the cerebel-
lum, the frontal cortex, the nucleus accumbens, the amyg-
dala, and hippocampus [13, 34, 41, 44], and MT2 receptor
transcripts were described in the hippocampus [45]. Note-
worthy, certain variability across species has been noticed
for melatonin receptors localization [46].
Melatonin has been implicated in the control of several
physiological processes by direct action on its G-protein
couple receptors [47]. One of the most studied functions of
melatonin is the regulation of sleep. Here, we conﬁrmed
the presence of MT2 receptors in the reticular thalamic
nucleus, where they mediate neuronal ﬁring and burst
activity related to the NREM sleep [10]. Moreover, we
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Fig. 12. Ultrastructural features of MT1 and MT2 receptors in selected brain areas. (A–F) MT1 immunogold labeling in the retrosplenial
cortex (A, B), dorsal raphe nucleus (C, D), and substantia nigra pars compacta (E, F). Generally, the membrane density of MT1 receptors
appeared higher in the SN. (G–L) MT2 immunogold labeling in the hippocampus (G, H), ventrolateral PAG (I, J), and substantia nigra
pars reticulata (K, L). Both melatonin receptors are exclusively somatodendritic and mainly membrane-bound (gold particles, arrowhead
as examples). Synaptic contacts are enclosed between small arrows, at: axon terminal; ax: axon; db: dendritic body. Scale bars: 500 nm.
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report the lack of MT1 receptors in this area, conﬁrming
the high speciﬁcity of melatonin receptor function in sleep
neurophysiology. Polysomnographic studies in MT1, MT2,
and double MT1-MT2 knockout mice have indeed shown
that both receptors have complementary or opposite
eﬀects [48], MT2 receptors being involved in NREM sleep,
whereas MT1 receptors in rapid eye movement (REM)
sleep [10, 48]. The presence of MT1 in the lateral hypothal-
amus [49] as well as in the superior colliculi, that sends
projections to the paramedian pontine reticular formation
(PPRF), which in turn coordinates the duration and direc-
tion of REM eye movements [50], strongly reinforces the
hypothesis of the involvement of this receptor in REM.
Previous binding studies also indicated the presence of
melatonin binding sites in the thalamus, in particular the
rat anteroventral and anterodorsal thalamic nuclei [51],
with similar expression patterns of MT1 and MT2 as
observed in our experiments.
For the ﬁrst time, we detected an abundant presence of
MT1, but not MT2, receptors in the dorsal raphe (DR), the
major source of 5-HT neurons that are involved in the
pathophysiology of depression and mood disorders [52]. In
agreement with these ﬁndings, MT1 receptors knockout
(but not MT2 knockout) mice show a depressive-melan-
cholic phenotype with circadian impairment of high ﬁring
5-HT neurons of the DR [53]. Furthermore, an inhibitory
modulation of the 5-HT ﬁring activity in the DR, mediated
by MT1 receptors, was also reported by our group [54].
Melatonin binding sites in the mammalian hypothala-
mus have been previously described and, predominantly,
melatonin actions on the premammilar area have been
linked to the control of the reproductive axis through
modulation of luteinizing hormone secretion [55]. We
found that both MT1 and MT2 receptors have a speciﬁc
distribution across the hypothalamus. MT1 receptors were
observed in the lateral hypothalamus and the medial emi-
nence, which may indicate a direct role of MT1 receptors
in the GnRH pulse generator [56]. The presence of MT1
receptors in the SCh has previously been observed in the
rat brain following in situ hybridization [43], and in the
human brain using immunohistochemistry [34], supporting
the role of melatonin on regulating biological circadian
rhythms. In our experiments, while conﬁrming the pres-
ence of MT1 receptors in the SCh, we could not detect a
signiﬁcant amounts of the MT2 protein in this region,
which is consistent with the absence of in situ hybridiza-
tion signal in this nucleus [43]. MT2 labeling was observed
in the paraventricular nucleus, magnocellular preoptic,
and supraoptic nuclei, areas involved directly and indi-
rectly in the secretion of oxytocin and vasopressin, sup-
porting a role of melatonin in the control of uterine
contractions and parturition [57].
We observed lower levels of MT1 immunoreactivity
across the diﬀerent subdivisions of the hippocampal forma-
tion. In line with this, previous studies reported low MT1
protein and mRNA expression in pyramidal cell of hippo-
campal human tissue [44, 58]. In contrast, MT2 receptors
seem to have a denser representation in the hippocampus,
as previously reported in humans [19]. Other studies have
reported that MT1 and MT2 receptor transcripts are pre-
dominately expressed in hippocampal layers CA1 and CA3
as well as in the DG [45], which is consistent with our
observations. In addition, similar to what we found in the
cerebral cortex at the protein level, lower MT1 mRNA lev-
els have been reported in the prefrontal and temporal cor-
tices and higher levels in the parietal and occipital cortices
[44]. Melatonin receptor labeling is also known to be
restricted to human cortical layers II–IV and absent from
layer I [59]. However, we observed a preferential MT1
labeling in the layers II/III and V, and MT2 labeling in lay-
ers V and VI. Noteworthy, abnormal expression of melato-
nin receptors, especially MT2, in the hippocampus and
cortex has been related to neurodegenerative processes that
aﬀect cognition such as Alzheimer disease [19, 58, 59].
Several studies have suggested that melatonin modulates
dopaminergic system, decreasing ﬁring of VTA dopamine
neurons in both light and dark phases [60], and inﬂuencing
the response to psychostimulants such as amphetamine
and cocaine [61, 62]. We were able to detect MT1 immuno-
reactive cells in the lateral portion of the nucleus accum-
bens shell (LAcbSh), and both receptors were detected in
the VTA. Accordingly in mice, neurons located in the
nucleus accumbens expressing D2 dopamine receptors and
neurons located in the VTA expressing TH are also posi-
tive for MT1 mRNA [41].
Recently, a postmortem study reported a decrease in the
expression (mRNA level) of both MT1 and MT2 receptors
in the substantia nigra (SN) of Parkinson’s disease patients
[63]. Interestingly, this ﬁnding is in accordance with our
observation of high MT1 receptor labeling densities in the
two subdivisions (pars compacta and pars reticulata) of the
SN. Furthermore, the expression of MT2 receptors in the
SN pars reticulata, the red nucleus, the oculomotor, pa-
rarubral nuclei, the GP, and the colliculi suggests that this
receptor might be involved in the motor eﬀects of systemic
administration of melatonin in these areas [64]. Yet, more
studies are needed to dissect the involvement of melatonin
in movement disorders.
Our ﬁndings demonstrate the presence of the MT1 pro-
tein in the AcbSh, CeM, MeAV, and SChVM, and of the
MT2 protein in the APir and AHiPM. In keeping with
these results, a constant inhibitory eﬀect of exogenous
melatonin administration has been observed in other neu-
ronal areas including the mesencephalic reticular forma-
tion, the striatum, the amygdala, and SCh [65–68].
Recent studies have aﬃrmed the role of MT2 receptor in
the control of inﬂammatory [69] and neuropathic pain
[70]. These pharmacological and physiological properties
of melatonin are supported by the presence of MT2 recep-
tors in brain areas involved in pain processing (PAG) [71],
speciﬁcally they are localized in the glutamatergic neurons
of PAG, controlling the activity of ON and OFF cells of
the descending nociceptive pathways [70].
MT1 and MT2 receptors were localized in areas known
to be implicated in anxiety and stress such as the septal
area, habenula, hippocampus, and DG [72, 73]. High
doses of melatonin and low doses of the selective MT2
agonist UCM765 showed anxiolytic-like eﬀects in animal
models of anxiety, similar to the benzodiazepine diazepam,
but without its locomotor side eﬀects [74].
One limitation of the study is not having used the MT1
and MT2 knockout as a control for these polyclonal anti-
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bodies. Unfortunately, knockout mice available are func-
tional knockout; the MT1 knockout have a deletion of the
exon 1 from the MT1 gene, whereas exon 2 is still present
[11], which may well produce nonfunctional truncated pro-
teins likely stained by our antibodies [34]. Similarly, in the
MT2 knockout mice, the ﬁrst exon of the MT2 receptor
gene was disrupted resulting in inactivation of the gene,
but some of the receptorial protein can be still expressed
[75].
In conclusion, this study is the ﬁrst to describe the regio-
nal and cellular localization of melatonin somatodendritic
receptors MT1 and MT2 in the rat brain. The diﬀerent local-
ization of MT1 and MT2 receptors in various brain regions
is suggestive of their functional specialization in the control
of several physiological functions. The elucidation of the
role of each of these receptors in brain physiology and path-
ophysiology will open novel opportunities for the develop-
ment of selective MT1 and MT2 receptor ligands.
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(Index of anatomical structures in alphabetic order, from the
stereotaxic atlas of Paxinos and Watson, [76])
3N oculomotor nucleus
3v 3rd ventricle
4v 4th ventricle
I, II, III cortical layers
AA anterior amygdaloid area
aca anterior commissure, anterior
AcbC accumbens nucleus, core
AcbSh accumbens nucleus, shell
acp anterior commissure, posterior
AD anterodorsal thalamic nucleus
AH anterior hypothalamic area
AL pituitary, anterior lobe
APir amygdalo-piriform transition
AHiPM amygdalo-hippocampal area, posteromedial
part
Aq aqueduct
ArcD arcuate hypothalamic nucleus, dorsal part
ArcM arcuate hypothalamic nucleus, medial part
CA1, CA2, CA3
ﬁelds CA1,2,3 of the hippocampus
cc corpus callosum
CeM central amygdaloid nucleus, medial part
CIC central nucleus of the inferior colliculus
cg cingulum
CPu caudate-putamen (dorsal striatum)
D3V dorsal 3rd ventricle
DLPAG dorsolateral periaqueductal gray
DLG dorsal lateral geniculate nucleus
DMPAG dorsomedial periaqueductal gray
DR dorsal raphe nucleus
DRV dorsal raphe nucleus, ventral part
f fornix
ﬁ ﬁmbria of the hippocampus
fr fasciculus retroﬂexus
GP globus pallidus
GrDG granular layer of the dentate gyrus
ic internal capsule
ICj islands of Calleja
ICjM islands of Calleja, major island
IEn intermediate endopiriform nucleus
Inf infundibulum
IPC interpeduncular nucleus, caudal subnucleus
IPR interpeduncular nucleus, rostral subnucleus
LA lateroanterior hypothalamic nucleus
LAcbSh lateral accumbens shell
Ld lambdoid septal zone
LDDM laterodorsal thalamic nucleus, dorsomedial part
LDVL laterodorsal thalamic nucleus, ventrolateral part
LHbL lateral habenular nucleus, lateral
LHbM lateral habenular nucleus, medial
LPAG lateral periaqueductal gray
LPLR lateral posterior thalamic nucleus, laterorostral
part
LPMR lateral posterior thalamic nucleus, mediorostral
part
LPO lateral preoptic area
LSD lateral septal nucleus, dorsal part
LSI lateral septal nucleus, intermediate part
LSV lateral septal nucleus, ventral part
LV lateral ventricle
M2 secondary motor cortex
MD mediodorsal thalamic nucleus
ME median eminence
MeAV medial amygdaloid nucleus, anteroventral part
mfb medial forebrain bundle
MHb medial habenular nucleus
ml medial lemniscus
mlf medial longitudinal fasciculus
MoDG molecular layer of the dentate gyrus
MPA medial preoptic area
mRT mesencephalic reticular formation
MS medial septal nucleus
mt mammillothalamic tract
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opt optic tract
Or Stratum oriens of the hippocampus
Pa paraventricular hypothalamic nucleus
PaR pararubral nucleus
PD pituitary, pars distalis
PI pituitary, pars intermedia
PLd paralambdoid septal nucleus
PN pituitary, pars nervosa
Po posterior thalamic nuclear group
PoDG polymorph layer of the dentate gyrus
PT pituitary, pars tuberalis
PVP paraventricular thalamic nucleus, posterior
Py pyramidal cell layer of the hippocampus
Rad Stratum radiatum of the hippocampus
Rh rhomboid nucleus
RMC red nucleus, magnocellular part
RP pituitary, Rathke’s pouch
RPC red nucleus, parvicellular part
Rt reticular thalamic nucleus
RSD retrosplenial dysgranular cortex
RSG retrosplenial granular cortex
SCh suprachiasmatic nucleus
SChVM suprachiasmatic nucleus, ventromedial part
SFi septoﬁmbrial nucleus
SIB substantia innominata, basal
sm stria medullaris
SNR substantia nigra, reticular part
SNC substantia nigra, compacta part
SNCD substantia nigra, compact part, dorsal tier
SNCM substantia nigra, compact part, medial tier
SNCV substantia nigra, compacta part, ventral tier
SO supraoptic nucleus
sox supraoptic decussation
Tu 1,2,3 olfactory tubercle cortical layers 1,2,3
VA ventral anterior thalamic nucleus
VDB nucleus of the vertical limb of the diagonal
band
VL ventrolateral thalamic nucleus
VLPAG ventrolateral periaqueductal gray
VM ventromedial thalamic nucleus
VP ventral pallidum
VPL ventral posterolateral thalamic nucleus
VPM ventral posteromedial thalamic nucleus
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